Trials / Terminated
TerminatedNCT00493441
AVN944 in Combination With Gemcitabine for the Treatment of Pancreatic Cancer
A Phase II Study of AVN944 in Combination With Gemcitabine for the Treatment of Pancreatic Cancer
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 28 (actual)
- Sponsor
- Vertex Pharmaceuticals Incorporated · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study was designed to find the optimum AVN944 dose to use in combination with gemcitabine in patients with pancreatic cancer and see if the combination of the 2 drugs was more effective for treating pancreatic cancer than using gemcitabine alone.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AVN944 | 150, 200, 250, 300, or 400 mg q12h |
Timeline
- Start date
- 2007-06-01
- Primary completion
- 2009-12-01
- Completion
- 2009-12-01
- First posted
- 2007-06-28
- Last updated
- 2020-09-30
Locations
16 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00493441. Inclusion in this directory is not an endorsement.